# A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

> **NCT07388602** · PHASE3 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** SCTC21C
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07388602
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07388602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07388602, "A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07388602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*